"Any contingent milestone payments will be paid in cash. The CVR payments to BioMimetic shareholders are structured as follows:
$3.50 per share upon FDA approval of Augment® Bone Graft; $1.50 per share upon the achievement of $40 million in trailing twelve month sales for all products contributed by BioMimetic; $1.50 per share upon the achievement of $70 million in trailing twelve month sales for all products contributed by BioMimetic."
Today: "Wright Medical Group, Inc. Announces Receipt of FDA Not Approvable Letter for Augment® Bone Graft"
Could be a bit of time before $3.50 is realized, if at all.